Finance

Roʻyxatlar
FLNA:BMV
Filana Therapeutics Inc
15,92 MX$
0,00%
(0,00) 1K
5-okt, 12:05:31 (GMT-6)  ·   MXN
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
FLNA tikeri uchun statistika yaratilmoqda...
Bozor kapitali
34,14 mln
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
56,00 MX$
52 haftalik eng past
15,92 MX$
Xodimlar soni
19
Bozor kapitali
34,14 mln
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
56,00 MX$
52 haftalik eng past
15,92 MX$
Xodimlar soni
19
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
Filana Therapeutics Inc haqida
CEO-
Xodimlar soni19
Asos solingan1998
Bosh ofislarOstin, Texas, Amerika Qo‘shma Shtatlari
Sektor-
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
-
-
-
-
Sotilgan mahsulotning tannarxi
3,96 mln
3,85 mln
4,54 mln
3,30 mln
Daromad narxi
3,96 mln
3,85 mln
4,54 mln
3,30 mln
Tadqiqot va ishlanmalarga xarajatlar
-
-
-
-
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
7,90 mln
5,70 mln
6,62 mln
6,09 mln
Operatsion xarajatlar
7,90 mln
5,70 mln
6,62 mln
6,09 mln
Jami operatsion xarajatlar
11,86 mln
9,55 mln
11,17 mln
9,39 mln
Operatsion daromad
-11,86 mln
-9,55 mln
-11,17 mln
-9,39 mln
Boshqa nooperatsion daromad
-114,00 ming
39,00 ming
48,00 ming
43,00 ming
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
-10,81 mln
-12,54 mln
-10,33 mln
-8,60 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
-10,81 mln
-8,54 mln
-10,33 mln
-8,60 mln
Daromad soligʻi boʻyicha xarajat
-
-
-
-
Amaldagi soliq stavkasi
-
-
-
-
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
-10,81 mln
-12,54 mln
-10,33 mln
-8,60 mln
Sof foyda marjasi
-
-
-
-
Har bir aksiya foydasi
-
-
-
-
Foizlar va investitsiyalardan olingan daromadlar
1,17 mln
974,00 ming
789,00 ming
747,00 ming
Foizlarni toʻlash xarajatlari
-
-
-
-
Foizlarni toʻlash boʻyicha sof xarajatlar
1,17 mln
974,00 ming
789,00 ming
747,00 ming
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
-11,73 mln
-9,18 mln
-10,92 mln
-9,15 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari